Health Technology Assessment

Health technology assessment (HTA) is the systematic, multidisciplinary evaluation of the properties and effects of a health technology — a drug, device, procedure, or programme — in order to inform decisions about its use. It synthesises evidence on clinical effectiveness, safety, cost, and broader social and ethical implications to support coverage, pricing, and policy decisions.

Definition

Health technology assessment is a multidisciplinary process that uses explicit methods to determine the value of a health technology across its life cycle, with the aim of informing decision-making to promote an equitable, efficient, and high-quality health system (per the 2020 international consensus definition).

Scope

This entry covers the purpose and methods of HTA: the questions it addresses, the dimensions of value it weighs (clinical benefit, cost-effectiveness, equity, organisational and ethical considerations), and its role in the resource-allocation decisions of health systems and reimbursement agencies. It is a reference topic on how technologies are appraised, not clinical guidance on any specific technology.

Core questions

• Does the technology work, and how does it compare with existing alternatives?
• Is the technology a good use of resources given its cost and the health it produces?
• What organisational, ethical, social, and equity implications follow from adopting it?
• How should the assessment inform coverage, pricing, and reimbursement decisions?

Key concepts

• Clinical effectiveness and safety
• Cost-effectiveness and economic evaluation
• Incremental cost-effectiveness ratio
• Quality-adjusted life year (QALY)
• Opportunity cost and the cost-effectiveness threshold
• Equity, ethical, and organisational considerations
• Evidence synthesis and decision modelling

Mechanisms

HTA combines a structured synthesis of clinical evidence — often through systematic review and meta-analysis — with economic evaluation that relates the additional cost of a technology to the additional health it produces. Health gains are commonly expressed in quality-adjusted life years, and the incremental cost-effectiveness ratio compares a technology with its comparator. Because budgets are finite, a technology's value is judged partly against an opportunity-cost threshold representing the health forgone elsewhere. Many HTA frameworks add explicit appraisal of equity, ethical, social, and organisational dimensions alongside the quantitative analysis (O'Rourke et al., 2020; Drummond et al., 2015; Gold et al., 1996).

Clinical relevance

HTA shapes which technologies are reimbursed and the conditions under which they are available, forming part of the system context in which clinicians practise. Familiarity with HTA helps health professionals interpret coverage and appraisal decisions; this entry describes the assessment process and is not a recommendation to use or avoid any particular technology.

Evidence & guidelines

HTA draws on systematic reviews, economic evaluations, and decision-analytic modelling rather than a single study design. International bodies such as INAHTA and HTAi have worked to harmonise terminology and methods, including the consensus definition described by O'Rourke et al. (2020); standard methodological references include Drummond et al. (2015) and Gold et al. (1996). Many countries operate national HTA agencies whose appraisals inform reimbursement.

History

Technology assessment in health care arose in the 1970s, when the rapid diffusion of new medical technologies and growing expenditure prompted governments to ask not only whether a technology worked but whether it was worth its cost. Over the following decades dedicated HTA agencies were established in many countries, methods for cost-effectiveness analysis were standardised, and international collaboration culminated in a shared definition of HTA in 2020 (O'Rourke et al., 2020).

Debates

Should there be an explicit cost-effectiveness threshold?

A fixed monetary threshold per QALY makes decisions transparent and consistent, but critics argue thresholds are hard to justify empirically, may not reflect true opportunity cost, and can sit uneasily with equity concerns; the appropriate basis for a threshold remains contested.

Key figures

• Michael Drummond
• Marthe Gold
• Milton Weinstein
• Michael Porter

Seminal works

• orourke-2020
• drummond-2015
• gold-1996

Frequently asked questions

What is the difference between HTA and a clinical trial?

A clinical trial generates primary evidence about whether a technology works, whereas HTA synthesises that and other evidence — including cost, equity, and ethical considerations — to inform a policy or coverage decision.

What is a QALY and why is it used in HTA?

A quality-adjusted life year combines length and quality of life into a single measure of health gain, allowing the benefits of very different technologies to be compared on a common scale within economic evaluation.